Henk Portengen - Concepedia

Author

Henk Portengen

Rotterdam University of Applied Sciences

Also Known As

H Portengen, H. PORTENGEN, H. Portengen, Henk Portengen

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

Rotterdam University of Applied Sciences Erasmus MC Erasmus University Rotterdam Erasmus MC Cancer Institute Klinikum rechts der Isar

About

Henk Portengen is an author at Rotterdam University of Applied Sciences specializing in medicine, breast cancer, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	23	2.6K
2	Cell Biology	7	7	1.1K
3	Education	1	1	19
4	Health Sciences	1	1	17
5	Biochemistry	1	1	25

Henk Portengen

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. John A. Foekens, Harry A. Peters, Maxime P. Look, PubMed Tumor BiologyBreast OncologyOncologyPlasminogen ActivationBreast Cancer Patients	2000	429
Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling Maurice P.H.M. Jansen, John A. Foekens, Iris L. van Staveren, Journal of Clinical Oncology	2005	331
Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. John A. Foekens, Henk Portengen, W L van Putten, PubMed Epidermal Growth FactorBreast OncologyGrowth HormoneMedicineTumor Recurrence	1989	219
c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. E. Berns, J.G.M. Klijn, W L van Putten, PubMed Her2/neu GenesBreast OncologyMedicineHer2/neu AmplificationPathology	1992	206
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. E. Berns, John A. Foekens, R. van Vossen, PubMed Breast OncologyPathologyComplete SequencingSystemic TherapyCancer Biology	2000	197
Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment Els M.J.J. Berns, John A. Foekens, Iris L. van Staveren, Gene Oncogene AmplificationBreast OncologyOncogenic AgentMedicineSystemic Treatment	1995	175
Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer John A. Foekens, Maxime P. Look, Harry A. Peters, JNCI Journal of the National Cancer Institute	1995	157
Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast Cancer John W.M. Martens, Inko Nimmrich, Thomas Koenig, Cancer Research	2005	130
The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study Jan G.M. Klijn, Maxime P. Look, Henk Portengen, Breast Cancer Research and Treatment Breast OncologyMedicinePrognostic ValueYear Follow-up StudyPathology	1994	122
Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: Correlation with steroid receptors Els M.J.J. Berns, Jan G.M. Klijn, Iris L. van Staveren, European Journal of Cancer Breast OncologyOncogenes C-mycOncogenic AgentMedicineSteroid Receptors	1992	121

Page 1